Business Description
Canbridge Pharmaceuticals Inc
ISIN : KYG1821D1097
Compare
Compare
Traded in other countries / regions
01228.Hong KongMF1.Germany IPO Date
2021-12-10Description
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | -1.13 | |||||
| Debt-to-Equity | -0.55 | |||||
| Debt-to-EBITDA | -0.41 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -16.49 | |||||
| Beneish M-Score | -3.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 98.3 | |||||
| 3-Year EBITDA Growth Rate | 27.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25 | |||||
| 3-Year FCF Growth Rate | 1.2 | |||||
| 3-Year Book Growth Rate | 72.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 39.93 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.73 | |||||
| 9-Day RSI | 20.63 | |||||
| 14-Day RSI | 25.42 | |||||
| 6-1 Month Momentum % | -21.21 | |||||
| 12-1 Month Momentum % | -73.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.21 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 133.66 | |||||
| Days Sales Outstanding | 100.27 | |||||
| Days Payable | 2185.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 10.55 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.96 | |||||
| Operating Margin % | -363.88 | |||||
| Net Margin % | -388.85 | |||||
| FCF Margin % | -242.81 | |||||
| ROE % | -275.28 | |||||
| ROA % | -100.22 | |||||
| ROIC % | -153.33 | |||||
| ROC (Joel Greenblatt) % | -365.09 | |||||
| ROCE % | -844.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.44 | |||||
| EV-to-EBIT | -0.4 | |||||
| EV-to-EBITDA | -0.43 | |||||
| EV-to-Revenue | 1.53 | |||||
| EV-to-FCF | -0.75 | |||||
| Earnings Yield (Greenblatt) % | -250 | |||||
| FCF Yield % | -536.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Canbridge Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 113.653 | ||
| EPS (TTM) (HK$) | -1.04 | ||
| Beta | 0 | ||
| Volatility % | 96.17 | ||
| 14-Day RSI | 25.42 | ||
| 14-Day ATR (HK$) | 0.024603 | ||
| 20-Day SMA (HK$) | 0.18235 | ||
| 12-1 Month Momentum % | -73.2 | ||
| 52-Week Range (HK$) | 0.112 - 1.1 | ||
| Shares Outstanding (Mil) | 424.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Canbridge Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Canbridge Pharmaceuticals Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Canbridge Pharmaceuticals Inc Frequently Asked Questions
What is Canbridge Pharmaceuticals Inc(HKSE:01228)'s stock price today?
The current price of HKSE:01228 is HK$0.12. The 52 week high of HKSE:01228 is HK$1.10 and 52 week low is HK$0.11.
When is next earnings date of Canbridge Pharmaceuticals Inc(HKSE:01228)?
The next earnings date of Canbridge Pharmaceuticals Inc(HKSE:01228) is 2025-03-28 Est..
Does Canbridge Pharmaceuticals Inc(HKSE:01228) pay dividends? If so, how much?
Canbridge Pharmaceuticals Inc(HKSE:01228) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers